# National Framework Agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders

> Contract award record from UK public-sector procurement sources.

## Key facts

- Public buyer: [NHS England](/buyers/nhs-england/contract-awards)
- Contract winner: Baxalta Limited
- Award value: £302,000,000
- Tender value: £302,000,000
- Award date: 24 November 2017
- Published: 19 December 2017
- Contract start: 1 February 2018
- Contract end: 31 January 2019
- Stage: awarded
- Procurement category: goods
- Notice ID: 6bab93eb-e9a0-4819-a8d7-210a780e9a11-187830
- OCID: ocds-b5fd17-da3b67f1-375b-4dc1-b407-bbddda599147

## Description

NHS framework agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders\. The framework will commence on 1\.2\.2018 for a period of 12 months until 31\.1\.2019 with options to extend up to a further 17 months\.

## Related contract awards

- [Transformation Delivery Services - Establishing Operational Excellence \(EOE\)](/contracts/ocds-b5fd17-b08595d2-8961-409b-9b62-7b01d7a64541): NHS England
- [Identity Access Management - Service Adoption and Enablement](/contracts/ocds-b5fd17-08ebad6c-84fb-4e62-9afd-d06d220dd3a5): NHS England
- [OutSystems licenses for MAPPTI \(AP&P\)](/contracts/ocds-b5fd17-521fbf90-6e93-4366-b3bc-47aa2efd447d): NHS England

## Source

[View the original notice on Contracts Finder](https://www.contractsfinder.service.gov.uk/Notice/6bab93eb-e9a0-4819-a8d7-210a780e9a11-187830)